Shilpa Medicare -Racing away on the Oncology API highway!

(Divyanshu Taneja) #589

Posted excellent results profit ups

(Sarabjeet Singh) #590

Finally we see YoY growth

(Ranjit Solkar) #591

Good set of results leading to a breakout in the Stock. Hopefully some of their filed ANDAs start to get approved soon. I understand it takes a lot lesser time (10 months in many cases) for ANDA approval now, so does anyone know when these 36 ANDAs were filed from Shilpa/partners?

(Harshit Goel) #592

Shilpa Medicare Ltd FY18 Annual Report Notes
Company gave a very detailed Annual Report this time. Product wise filing details in every regulated market and the expansion plans are all give in great details. Going forward main focus of the company seems to be on US market and Biosimilar segment. Following are the highlights from the AR.

  • On standalone basis the Company reported operating revenues of Rs. 74394.60 lakcs as against Rs. 73789.90 lacs and a Net Profit of Rs. 13432.19 lacs as against Rs. 12562.30 lacs in the previous year
  • On consolidated basis the Company reported operating revenues of Rs. 791.53. cr as against Rs. 783.81 cr and a Net Profit of Rs. 102.86 cr as against Rs. 104.45 cr in the previous year
  • Sales from
    Bulk Drugs / Intermediates = Rs. 621.69 cr (Rs. 649.80 cr)
    Formulation = Rs. 90.04 cr (Rs. 48.46 cr)
    FPS/ MEIS Licences = Rs. 18.67 cr (Rs. 17.53 cr)
    Power = Rs. 5.32 cr (Rs. 4.82 cr)
    Trading= Rs. 9.55 cr (Rs. 9.24 cr)
    Product Development = Rs. 39.46 cr (Rs. 49.08 cr).
  • Shilpa Medicare has two API plants with world class state of art facilities at Raichur. The units are cGMP compliant and are approved by national & international regulatory bodies like USFDA, EU, Korean FDA, Cofepris-Mexico, TPD-Canada, PMDA-Japan and TGA-Australia.
  • Shilpa Medicare Limited – Finished Dosage Formulation Facility is a World Class GMP compliant Facility engaged in manufacturing of potent drugs- which includes liquid and lyophilized injectables in vials, sterile dry powder injectables in vials, oral solid dosage form (Tablets and hard gelatine capsules). The facility is approved by various regulatory agencies including USFDA, EUGMP, ANVISA & COFEPRIS. This facility consists of Oral Solid Block with two commercial scale tablet manufacturing and one commercial scale capsule manufacturing line approved by USFDA. Three separate Injectable blocks consists of two liquid-lyophilisation commercial scale manufacturing lines approved by USFDA and 3rd Injectable combi-line for handling of liquid, lyophilized and Dry Powder Injectable under qualification. Fully automatic packing area is under installation and commissioning.
  • Domestic Sales = Rs. 321 cr (40.58%), Exports = Rs. 470.11 cr (59.42%).
  • Sales from USA increased from Rs. 62.14 cr to Rs. 112.27 cr, increase of 80% yoy.
  • Sales from Europe decreased from Rs. 414.65 cr to Rs. 284.38 cr, decrease of 31% yoy.
  • Domestic Sales increased from Rs. 226.85 cr to Rs. 321.42 cr, increase of 41% yoy.
  • Capex of Rs. 118 cr in FY18 in Tangible assets and Rs. 31 cr Capex in Intangible assets.
  • Cash and Mutual Funds of Rs. 193 cr.
  • Debt reduced from Rs. 240 cr in FY17 to Rs. 191 FY18.
  • EBITDA margins declined from 21.9% to 20.44% yoy.
  • Finance cost of Rs. 2.66 cr on average loan of Rs. 215 cr is a bit low, interest cost is being capitalised.
  • Total R&D exp during the year is Rs. 67.77 cr, 8.5% of sales.
  • The Company has invested in containment technologies for manufacture of oncology drug substances and made our manufacturing process sustainable. The Company has invested in latest available technologies like Bipolar system from Japan, first in India to manufacture one of our products there by reduced the water consumption by about 10 fold in that product.
  • In FY 17-18, the Company has filed two ANDAs with paragraph IV certification as First to File (FTF).
  • In FY 17-18, Shilpa and its group companies have filed 34 patent applications taking the cumulative total to 247 patent applications in India and other countries. Shilpa received grants for 9 patents.
  • In FY 2018-19 Shilpa has plans
    for filing 5 ANDAs with paragraph IV certification with US FDA, out of which two could be first-to-file ANDAs.
    Shilpa & it’s Partners has plans for filing of two 505(b)2 NDAs.
    Shilpa plans to file at least one NDA for its differentiated product.
  • Regulatory Filings (API)
    Cumulative USDMF Filings: 30 products
    Cumulative EDQM CEPs: 11 products
    Cumulative EUDMF Filings: 15 products
  • Regulatory Inspections and approvals.
    During the year under review, the Company has received EIR from USFDA, for the inspection conducted during the period of November, 2017 for FDF manufacturing site, Jadcherla.
    During the year under review, two API facilities located at Raichur and FDF facility at Jadcherla inspected & approved by European authority from Austria (AGES) for GMP compliance.
    During the year under review, two API facilities located at Raichur, Karnataka, i.e. Unit-1: Deosugur Industrial Area, Deosugur, Raichur, Karnataka, India and Unit-2: Raichur Industrial Growth Centre, Chicksugur, Raichur, Karnataka, India, inspected by USFDA for PAI. EIR received.
    US ANDA’s filed: 7 Products.
    EU Dossiers filed: 7 Products
    Cumulative ANDA’s filings: 15 Products.
    Cumulative clients ANDA’s filings: 9 Products.
    Cumulative EU dossier filings: 14 Products
  • Looking to the market potential, we have planned to build a state of art manufacturing facility of Transdermal Patch and Oral Films at Dobaspet, Bangalore. The plant construction work is already initiated and expected to be completed by end of year 2018.The High Quality critical equipment’s required for the above formulations manufacturing are already ordered from known European vendors and are expected to be received at site between Jan to June’19. Capacities are planned looking to all markets in first phase. A space for future expansion is allocated for capacity increment. Site will be ready for qualification by September 2019.
  • We have also planned to have a state of art Research and Development centre at Bangalore along with a pilot plant facility for potent and non-potent formulation. Layouts are under approval process and construction shall be initiated soon. This facility also will be ready by September 2019. Initial discussion initiated with Vendors for equipment finalization.
  • During the past year Shilpa received two product approvals in US for Azacitidine and Capecitabine. Those products are being commercialized by partners in the US.
  • In order to address the consolidated and diverse group of customers in US. Shilpa hired in January 2018 a seasoned Executive Mr. Adam Levitt as CEO (US Market). He has a diverse background in the generic pharmaceutical business. He is an experienced leader having worked for global and International generic companies. During his career, he has developed strategies, built multiple organizations while creating sustainable value in both retail and Institutional markets.

Biosimilar Segment

  • The amalgamation of Navya Biologicals Pvt Ltd with your company was completed in late November 2017 and now is your company’s Biologics Division, based out of Hubli-Dharwad in Karnataka. This transaction has enabled your company to save about 5-7 years in development timelines for biosimilars. The company now has 13 biosimilars in its pipeline and is dominated by drugs catering to the autoimmune disorders and oncology segments, with 7 of the top 10 biologics in its pipeline. The remaining are niche, high margin opportunities catering to high unmet clinical needs. The company has also filed 3 platform patents and is pursuing these in global markets.
  • The first biosimilar is poised to enter human clinical studies later this year. The innovator has a global market of $8 billion pa for this molecule, while the biosimilar opportunity is at $3-3.2 billion per annum. Three other molecules are ready to complete preclinical studies this year. Your company expects to commercialize its first biosimilar in 2019 in India, with the others following suit in 2020-21. We expect to be in a position of strength to penetrate the global window of opportunity for global biosimilars through strategic partnerships in the global markets, while opportunistically continuing to build our marketing channels in a few strategically important markets.
  • Your company has taken steps to become a vertically integrated biopharmaceutical player, by acquiring 11 acres of industrial land in Belur industrial area, Dharwad and initiating set up a world class biologics manufacturing unit (including fill & finish), employing best in class manufacturing technologies, that reduce the footprint of the facility by about 40%, thereby reducing the capital and operational costs significantly. Phase 1 of the facility is expected to be commissioned in the first half of 2019 and will cater to global biologics markets. The biologics unit is expected to emerge as the next growth driver for your company in the coming decade and look forward to an exciting future in biopharmaceuticals.
  • The global prescription pharmaceutical market is estimated at $811 Billion in 2018 and expected to grow at 6.5% for the next 5 years. Of this, the generics market is estimated at $90 billion and expected to grow at a similar rate. The above figures hide the new shifting reality – Biologics now constitute about 27% of prescription pharma sales, while biologics share within the top 100 drugs is ~50% – showcasing the effectiveness of these drugs, whose target markets are – oncology, Autoimmune disorders, hematology and diabetes.
  • Genericized biologics (biosimilars) growth in the generics market is expected to parallel the growth of innovator biologics above, thus presenting the largest opportunity for growth over the next decade, with sales of biosimilars expected to hit $20-23 billion by 2023-24 globally.

Subsidiaries and JVs

  • After completion of 3 years of establishment i.e., by 2018 January, INM Technologies has received DSIR certification. For FY18 Sales = Rs. 4.31 cr, PAT = (Rs. 9.52 cr), Holding 75%.
  • As a result of continued efforts in the research and product development, STPL had developed the most sought after novel drug delivery dosage form– orally disintegrating strip/film and obtained the manufacturing and marketing licenses for this dosage form in India and abroad. For FY18 Sales = Rs. 3.11 cr, PAT = (Rs. 1.84 cr), Holding 100%.
    ODS products of Shilpa Therapeutics have already been launched in India by prominent pharma companies viz., Mankind, Delvin, Alkem, Leads Pharma and Rx Drugs.
    Shilpa Therapeutics has also extended its business to the external markets with its ODS products launched in Kenya, Yemen, Honduras and many other countries to follow.
    Registration process like dossier submission is under process in many countries like Francophone countries, Malaysia, Thailand, Myanmar and Cambodia.
    STPL has obtained manufacturing and marketing license from the Drugs Control General (India), New Delhi for 7 products and 8 products are in pipeline.
  • Koanaa Healthcare GmbH will act as a regulatory hub in Austria and is currently focused on getting commercial cooperation’s with other pharmaceutical companies. First cooperation with Amring is already achieved and intensive discussions to expand the existing partnership are ongoing. For FY18 Sales = Rs. 1.41 cr, PAT = (Rs. 10.27 cr), Holding 100%.
  • RAICHEM MEDICARE PRIVATE LIMITED The Company has entered into Share Purchase agreement with joint partner ICE SPA Italy to dispose off its entire stake in the Company to the joint partner ICE SPA Italy. According to the terms of agreements, the Company has so far disposed off 24% stake in the Company for which the Consideration has already been received. The Company is in the process of disposing the remaining 26% with prior approval of Reserve Bank of India. Loss attributable to Shilpa Medicare was Rs. 8.83 cr in FY18. Equity Investment = Rs. 14.02 cr, Preference Share Investment = Rs. 18.50 cr and Loans Given = Rs. 5.08 cr. Total Investment = Rs. 37.60 cr. Trade Receivables = Rs. 49.86 cr.


Disclosure: Invested
Link to Annual Report 2018:

(Ayush Mittal) #595

Hi Harshit,

Thanks for putting up the notes. Its a pretty detailed report this time from Shilpa with some discussion and insights on several of their business segments and positive undertone. It will take time to digest and understand it well enough.
The company seems to be capitalizing some of the R&D expenses now…need to understand this.

I have been concerned with the announcement of the dis-investment of the JV (though its good for short term as it was making losses and the company will get money also). Is the business with ICE also at risk from longer term perspective?

Also, the pace of growth from new investments has been much lower than my expectations.

I also wonder that to be successful in bio-similar the company would have to make a lot of investment…how will that affect the company?

I hope some answers are there at the AGM .

Disc: Not invested

(MONK88888) #596

Hi Harshit & Ayush,

Thank you Harshit for summarising the AR. Ayush as far as I understand , ICE CRAMS has not been working well for Shilpa post their Raichem venture (some issues on uptake from ICE & margins pertaining to the uptake) . My understanding is that post divestment , they would continue to contribute around 150cr till 2019 or 2020 (not that clear) but none after that as ICE would be technically manufacturing in that unit purchased from Shilpa medicare-not sure what will fill that gap
Not happy with Capex investment , expected a substantial growth in capex post Tano placement.
European sales drop is something we need to check with CEO as they were quite bullish Euro area
Also the interest cost does not tally with debt exposure (like harshit mentioned -interest capitalised)
still positive on this scrip & hoping that ANDA approvals drive the next phase of growth.
Discl: Invested

(Ayush Mittal) #597

As per recent interview of MD, they are looking for high growth from formulations…I think in the interview he mentioned scaling up US formulation business from 30-40 Cr to 200 Cr this year and then again a good growth. Perhaps this will replace the drop in ICE business.

The drop in EU business would be perhaps due to shifting of ICE business to the JV

But yes, I agree. Things haven’t been as expected. One needs more clarity